AMO Pharma

AMO Pharma is building a portfolio of new medicines targeting serious and debilitating diseases, with a particular focus on rare and orphan genetic disorders. The privately held emerging biopharmaceutical company, headquartered in London, identifies and advances promising therapies for patient populations facing significant unmet need, guided by the principle that clinical development should deliver measurable value to patients at every stage of the journey.

The pipeline reflects that commitment. AMO Pharma is progressing multiple candidates, including AMO-01, AMO-02, and AMO-04, across conditions that include Phelan-McDermid Syndrome, Rett Syndrome, and congenital myotonic dystrophy. The REACH-CDM pivotal clinical trial for congenital myotonic dystrophy represents a significant milestone in the company's development programme. Each indication falls within the rare or orphan disease space, where AMO Pharma's strategy is to identify assets with high potential impact and advance them through all phases of development, from early research through to potential approval.

The company is led by a team of seasoned industry professionals who bring extensive experience in biomedical science, research, and asset acquisition across all phases of pharmaceutical development. This experienced leadership team combines deep scientific knowledge with commercial expertise, enabling a disciplined approach to candidate selection and clinical execution. AMO Pharma also maintains an active partnerships function, reflecting a business model that combines internal expertise with external collaboration to move treatments forward for underserved patient communities.

Further information is available at amo-pharma.com.